

Notice reference number: #1277.15.10

Notice date: 23/10/2015

What's this about?

Effective date: 23/10/2015

<input checked="" type="radio"/> ASX Trade	<input type="radio"/> ASX 24	<input type="radio"/> ASX TECH				
<input checked="" type="radio"/> Trading	<input type="radio"/> Clearing	<input type="radio"/> Settlement	<input type="radio"/> ALC	<input type="radio"/> ASX NET		
<input type="radio"/> Operations	<input type="radio"/> Technology	<input type="radio"/> Market Data	<input type="radio"/> Rules	<input checked="" type="radio"/> Compliance	<input type="radio"/> Risk	<input checked="" type="radio"/> Other

Title

FarmaForce Limited – Admission and Commencement of Official Quotation

Description

FarmaForce Limited (ASX Code: FFC) (the Company) was admitted to the official list of ASX Limited (ASX) on Friday, 23 October 2015.

Official quotation of the Company's securities is expected to commence at 11:00am AEDT on Tuesday, 27 October 2015. The Company has raised \$5,077,041 under the replacement prospectus dated 10 August 2015 issued by the Company (Prospectus) by the issue of 16,923,471 ordinary fully paid shares at an issue price of \$0.30 per share.

Quoted Securities: 30,375,134 ordinary fully paid shares

ASX Code: FFC

Time: 11:00am AEDT

Date: Tuesday, 27 October 2015

ASX Trade Abbreviation: FARMAFORCE

ISIN: AU000000FFC7

Home Branch: Sydney

Industry Classification: 3510 Health Care Equipment & Services

Registered Office: Level 3, 222 Clarence Street
Sydney NSW 2000

Principal Place of Business: Level 3, 222 Clarence Street
Sydney NSW 2000

Phone: 02 8239 5400
Email: investor.relations@iq3corp.com
Website: www.farmaforce.com

Company Secretary: Kelvin Boateng

<u>Share Registry:</u>	Boardroom Pty Limited Level 12, 225 George Street Sydney NSW 2000
<u>Balance Date:</u>	30 June
<u>CHESS:</u>	Participating. The Company will also operate an issuer sponsored subregister
<u>Place of Incorporation:</u>	New South Wales
<u>Dividend Policy:</u>	Refer to section 2.12 on page 34 of the Prospectus
<u>Activities:</u>	Pharmaceutical contract sales
<u>Lead Manager:</u>	iQ3Corp Ltd
<u>Restricted Securities:</u>	41,667 fully paid ordinary shares escrowed until 11 July 2016 483,333 fully paid ordinary shares escrowed until 23 July 2016 4,592,503 fully paid ordinary shares escrowed until 25 July 2016 433,333 fully paid ordinary shares escrowed until 28 July 2016 18,402,500 options exercisable at \$0.20 expiring on a date which is 36 months after the date of official quotation, escrowed for 12 months from the date of official quotation 91,575,010 fully paid ordinary shares escrowed for 24 months from the date of official quotation 900,000 options exercisable at \$0.20 expiring on a date which is 36 months after the date of official quotation, escrowed for 24 months from the date of official quotation

[What do I need to do and by when?](#)

For further details, please refer to the Company's Prospectus and website.

[Need more information?](#)

If further information is required in relation to the Offer, please contact Boardroom Pty Limited on 1300 737 760.

Issued by
Andy Weaver

Contact Details
(02) 9227 0517

Disclaimer